Share class: Evotec SE

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 17,77,63,524 15,77,92,700 ( 88.77 %) 2,49,915 ( 0.1406 %) 88.77 %

Major shareholders: Evotec SE

NameEquities%Valuation
Excalibur Luxco SARL
9.974 %
1,77,30,913 9.974 % 131 M €
Mubadala Investment Co. (Investment Company)
6.458 %
1,14,81,502 6.458 % 85 M €
MAK Capital One LLC
5.28 %
93,86,434 5.28 % 69 M €
T. Rowe Price International Ltd.
4.571 %
81,27,117 4.571 % 60 M €
Black Creek Investment Management, Inc.
3.129 %
55,63,329 3.129 % 41 M €
Global Alpha Capital Management Ltd.
3.059 %
54,37,444 3.059 % 40 M €
Franklin Templeton Institutional LLC
2.96 %
52,62,750 2.96 % 39 M €
T. Rowe Price Associates, Inc. (IM)
2.916 %
51,83,579 2.916 % 38 M €
Connor, Clark & Lunn Investment Management Ltd.
2.892 %
51,41,392 2.892 % 38 M €
Lupus alpha Asset Management AG
0.2846 %
5,06,000 0.2846 % 4 M €
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
NameEquities%Valuation
Mubadala Investment Co. (Investment Company)
5.172 %
45,97,701 5.172 % 17 M €
Wellington Trust Co., NA
1.609 %
14,29,899 1.609 % 5 M €
Aperio Group LLC
1.463 %
13,00,009 1.463 % 5 M €
DCF Advisers LLC
1.349 %
11,98,993 1.349 % 4 M €
WCM Investment Management LLC
0.6293 %
5,59,343 0.6293 % 2 M €
0.6236 %
5,54,287 0.6236 % 2 M €
Morgan Stanley Capital Services LLC
0.3543 %
3,14,912 0.3543 % 1 M €
Pitcairn Co., Inc.
0.182 %
1,61,769 0.182 % 590 457 €
Citadel Securities GP LLC
0.108 %
96,045 0.108 % 350 564 €
LPL Financial LLC
0.1065 %
94,625 0.1065 % 345 381 €
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional37.72%
Other10.99%
ABC arbitrage SA0.31%
Individuals0.21%
Unknown50.77%

Based on 1000 largest holdings

Geographical origin of shareholders

United States
14.37%
Germany
10.97%
Canada
9.08%
United Arab Emirates
9.04%
United Kingdom
4.6%
France
0.44%
Luxembourg
0.29%
Individuals
0.21%
Austria
0.17%
Switzerland
0.02%
Spain
0.02%
Cayman Islands
0.01%
Ireland
0.01%

Based on 1000 largest holdings

Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,788